|
1
|
Hippocrates: The Genuine Works of
Hippocrates. I and II. Adams F: New York: William Wood and Company;
1886
|
|
2
|
Copeman WS: A short history of the gout
and the rheumatic diseases. Berkeley and Los Angeles: University of
California Press; 1964
|
|
3
|
Kuo CF, Grainge MJ, Mallen C, Zhang W and
Doherty M: Rising burden of gout in the UK but continuing
suboptimal management: A nationwide population study. Ann Rheum
Dis. 72:661–667. 2015. View Article : Google Scholar
|
|
4
|
di Giovine FS, Malawista SE, Thornton E
and Duff GW: Urate crystals stimulate production of tumour necrosis
factor alpha from human blood monocytes and synovial cells.
Cytokine mRNA and protein kinetics, and cellular distribution. J
Clin Invest. 87:1375–1381. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiltz C, Lioté F, Prudhommeaux F,
Meunier A, Champy R, Callebert J and Bardin T: Monosodium urate
monohydrate crystal induced inflammation in vivo: Quantitative
histomorphometric analysis of cellular events. Arthritis Rheum.
46:1643–1650. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Daoussi D, Andonpoulos I and Andonopoulos
AP: ACTH as a treatment for acute crystal induced arthritis: Update
on clinical evidence and mechanisms of action. Semin Arthritis
Rheum. 43:648–653. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vanja SK, Rathinam VA and Fitzgerald KA:
Mechanisms of inflammasome activation: Recent advances and novel
insights. Trends Cell Biol. 25:308–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yagnik DR, Hillyer P, Marshall D, Smythe
CD, Krausz T, Haskard DO and Landis RC: Noninflammatory
phagocytosis of monosodium urate monohydrate crystals by mouse
macrophages. Implications for the control of joint inflammation in
gout. Arthritis Rheum. 43:1779–1789. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yagnik D: Macrophage derived platelet
activating factor implicated in the resolution phase of gouty
inflammation. Int J Inflam. 2014:5264962014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Landis RC, Yagnik DR, Florey O,
Philippidis P, Emons V, Mason JC and Haskard DO: Safe disposal of
inflammatory monosodium urate monohydrate crystals by
differentiated macrophages. Arthritis Rheum. 46:3026–3033. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yagnik DR, Evans BJ, Florey O, Mason JC,
Landis RC and Haskard DO: Macrophage release of transforming growth
factor beta1 during resolution of monosodium urate monohydrate
crystal-induced inflammation. Arthritis Rheum. 50:2273–2280. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Howard KM, Abdel-Al M, Ditmyer M and Patel
N: Lipopolysaccharide and platelet-activating factor stimulate
expression of platelet-activating factor acetylhydrolase via
distinct signaling pathways. Inflam Res. 60:735–744. 2011.
View Article : Google Scholar
|
|
13
|
Richette P, Doherty M, Pascual E, Barskova
V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL,
Janssens H, et al: 2016 updated EULAR evidence-based
recommendations for the management of gout. Ann Rheum Dis.
76:29–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elstad MR, Stafforini DM, McIntyre TM,
Prescott SM and Zimmerman GA: Platelet-activating factor
acetylhydrolase increases during macrophage differentiation. A
novel mechanism that regulates accumulation of platelet-activating
factor. J Biol Chem. 25:8467–8470. 1989.
|
|
15
|
Narahara H and Johnston JM: Effects of
endotoxins and cytokines on the secretion of platelet-activating
factor-acetylhydrolase by human decidual macrophages. Am J Obstet
Gynecol. 169:531–537. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu X, Zimmerman GA, Prescott SM and
Stafforini DM: The p38 MAPK pathway mediates transcriptional
activation of the plasma platelet-activating factor acetylhydrolase
gene in macrophages stimulated with lipopolysaccharide. J Biol
Chem. 279:36158–36165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hattori K, Hattori M, Adachi H, Tsujimoto
M, Arai H and Inoue K: Purification and characterization of
platelet-activating factor acetylhydrolase II from bovine liver
cytosol. J Biol Chem. 270:22308–22313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stafforini DM, McIntyre TM, Zimmerman GA
and Prescott SM: Platelet-activating factor acetylhydrolases. J
BiolChem. 272:17895–17898. 1997.
|
|
19
|
Stafforini DM, Prescott SM, Zimmerman GA
and McIntyre TM: Mammalian platelet-activating factor
acetylhydrolases. Biochim Biophys Acta. 1301:161–173. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stafforini DM, Prescott SM and McIntyre
TM: Human plasma platelet-activating factor acetylhydrolase.
Purification and properties. J Biol Chem. 262:4223–4230.
1987.PubMed/NCBI
|
|
21
|
Neto Castro Faria HC, Stafforini DM,
Prescott SM and Zimmerman GA: Regulating inflammation through the
anti-inflammatory enzyme platelet-activating
factor-acetylhydrolase. Mem Inst Oswaldo Cruz. 100 Suppl 1:S83–S91.
2005. View Article : Google Scholar
|
|
22
|
Blank ML, Lee T, Fitzgerald V and Snyder
F: A specific acetylhydrolase for
1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and
platelet-activating lipid). J Biol Chem. 256:175–178.
1981.PubMed/NCBI
|
|
23
|
Akira S, Misawa T, Satoh T and Saitoh T:
Macrophages control innate inflammation. Diabetes Obes Metab. 15
Suppl 3:S10–S18. 2013. View Article : Google Scholar
|
|
24
|
So AK and Martinon F: Inflammation in
gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol.
13:639–647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Triggiani M, Granata F, Giannattasio G and
Marone G: Secretory phospholipases A2 in inflammatory and allergic
diseases: Not just enzymes. J Allergy Clin Immunol. 116:1000–1006.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perelman B, Adil A and Vadas P:
Relationship between platelet activating factor acetylhydrolase
activity and apolipoprotein B levels in patients with peanut
allergy. Allergy Asthma Clin Immunol. 10:202014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakajima K, Murakami M, Yanoshita R,
Samejima Y, Karasawa K, Setaka M, Nojima S and Kudo I: Activated
mast cells release extracellular type platelet-activating factor
acetylhydrolase that contributes to autocrine inactivation of
platelet-activating factor. J Biol Chem. 272:19708–19713. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vadas P, Browning J, Edelson J and
Pruzanski W: Extracellular phospholipase A2 expression and
inflammation: The relationship with associated disease states. J
Lipid Mediat. 8:1–30. 1993.PubMed/NCBI
|
|
29
|
Miguélez R, Palacios I, Navarro F,
Gutierrez S, Sanchez-Pernaute O, Egido J, González E and
Herrero-Beaumont G: Anti-inflammatory effect of a PAF receptor
antagonist and a new molecule with antiproteinase activity in an
experimental model of acute urate crystal arthritis. J Lipid Mediat
Cell Signal. 13:35–49. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tjolker LW, Eberhardt C, Unger J, Trong
HL, Zimmerman GA, McIntyre TM, Stafforini DM, Prescott SM and Gray
PW: Plasma platelet activating factor acetylhydrolase is a secreted
phospholipase A2 with a catalytic triad. J Biol Chem.
270:25481–25487. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gomes RN, Bozza FA, Amâncio RT, Japiassú
AM, Vianna RC, Larangeira AP, Gouvêa JM, Bastos MS, Zimmerman GA,
Stafforini DM, et al: Exogenous platelet activating factor
acetylhyhrolase reduces mortality in mice with systemic
inflammatory response syndrome and sepsis. Shock. 26:41–49. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Opal S, Laterre PF, Abraham E, Francois B,
Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A,
et al: Recombinant human platelet-activating factor acetylhydrolase
for treatment of severe sepsis: Results of a phase III,
multicenter, randomized, double-blind, placebo-controlled, clinical
trial. Crit Care Med. 32:332–341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Howard KM and Olson MS: The expression and
localization of plasma platelet-activating factor acetylhydrolase
in endotoxemic rats. J Biol Chem. 275:19891–19896. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li JM, Datto MB, Shen X, Hu PP, Yu Y and
Wang XF: Sp1, but not Sp3, functions to mediate promoter activation
by TGF-beta through canonical Sp1 binding sites. Nucleic Acids Res.
26:2449–2456. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coutinho AE and Chapman KE: The
anti-inflammatory and immunosuppressive effects of glucocorticoids,
recent developments and mechanistic insights. Mol Cell Endocrinol.
335:2–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou G, Marathe GK, Hartiala J, Hazen SL,
Allayee H, Tang WH and McIntyre TM: Aspirin hydrolysis in plasma is
a variable function of butyrylcholinesterase and
platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). J Biol
Chem. 288:11940–11948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dandona P, Ghanim H, Sia CL, Green K,
Abuaysheh S, Dhindsa S, Chaudhuri A and Makdissi A: A mixed
anti-inflammatory and pro-inflammatory response associated with a
high dose of corticosteroids. Curr Mol Med. 14:793–801. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo N and Peng Z: Mg132, a proteasome
inhibitor, induces apoptosis in tumour cells. Asia Pac J Clin
Oncol. 9:6–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dalbeth N, Lauterio TJ and Wolfe HR:
Mechanism of action of colchicine in the treatment of gout. Clin
Ther. 36:1465–1479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Łuczaj W, Gindzienska-Sieskiewicz E,
Jaroka-karpowicz I, Andisic L, Sierakowski S, Zarkovic N, Waeg G
and Skrzydlewska E: The onset of lipid peroxidation in rheumatoid
arthritis: Consequences and monitoring. Free Radic Res. 50:304–313.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang P, Liu J, Tan B, Zhu F and Fang L:
Hypercoagulable state is associated with NF-kappa B activation and
increased inflammatory factors in patients with rheumatoid
arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:364–368.
2016.(In Chinese). PubMed/NCBI
|
